Trial Search Results

Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer

This 2-part, Phase 1/2 study will test investigational cancer drugs known as CRS-207, epacadostat, and pembrolizumab. The purpose of this study is to find out how safe it is to give the investigational drugs to women with platinum-resistant ovarian, fallopian tube, or peritoneal cancer and if it helps patients with these types of cancer live longer or can help shrink or slow the growth of cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Aduro Biotech, Inc.

Collaborator: Incyte Corporation

Intervention(s):

  • Biological: CRS-207
  • Drug: Epacadostat
  • Biological: Pembrolizumab

Phase:

Phase 1/Phase 2

Eligibility


Inclusion Criteria:

   1. Histologically-confirmed disease

      - Phase 1: Individuals with epithelial ovarian cancer, fallopian tube carcinoma, or
      primary peritoneal carcinomas who are considered to have platinum-resistant
      disease (progression within 6 months from completion of platinum-based
      chemotherapy).

      - Phase 2: Individuals with epithelial ovarian cancer, fallopian tube carcinoma, or
      primary peritoneal carcinomas who are considered to have platinum-resistant
      disease (progression within 6 months from completion of a minimum of 4 platinum
      therapy cycles).

   2. Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors
   (RECIST) v1.1

   3. Agree to provide core biopsies at baseline and at Cycle 2 Day 15

   4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

   5. Available archived tumor tissue for central analysis

   6. Adequate organ and marrow function

Exclusion Criteria

   1. Platinum-refractory disease (progression during the first platinum-based chemotherapy)

   2. Major surgical procedure within 4 weeks prior to Study Day 1

   3. Inaccessible tumors or for whom biopsy is contraindicated

   4. Clinically significant ascites

   5. Phase 2 only: Previous treatment with >3 chemotherapy regimens for locally advanced or
   metastatic disease

   6. Active bowel obstruction, or hospitalization for bowel obstruction within 2 months
   prior to screening

   7. Require parenteral nutrition

   8. Hospitalization within 2 weeks prior to screening

   9. Received any anticancer medication or therapy in the 21 days prior to study Day 1

10. Prior monoclonal antibody treatment within 4 weeks before study Day 1

11. History of listeriosis or previous treatment with a listeria-based immunotherapy

12. Known allergy to both penicillin and sulfa antibiotics

13. Any immunodeficiency disease or immune-compromised state

14. Received prior immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1, anti PDL-1)
   and any other antibody or drug specifically targeting T-cell costimulation or an IDO
   inhibitor

15. Pregnant or breastfeeding

16. Clinically significant heart disease

17. Valvular heart disease that requires antibiotic prophylaxis for prevention of
   endocarditis

18. History of any autoimmune disease which required systemic therapy in the past 2 years

19. Diagnosed with another malignancy within the past 3 years

20. Currently receiving therapy with a UDP-glucuronosyltransferase 1A9 inhibitor including
   diclofenac, imipramine, ketoconazole, mefenamic acid, and probenecid

21. Receiving monoamine oxidase inhibitor (MAOIs) or a drug which has significant MAOI
   activity (meperidine, linezolid, methylene blue) within the 21 days before screening

22. Had prior serotonin syndrome

23. Has implanted medical devices that pose high risks for colonization and cannot be
   easily removed

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting